Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’s disease. Despite physician familiarity with Omvoh, gastroenterologists surveyed by Spherix Global Insights prefer Johnson & Johnson’s Tremfya (currently awaiting approval) for Crohn’s disease treatment. This preference stems from a perception of Tremfya as a more significant advancement over current treatment options.

This approval is crucial for Crohn’s disease patients as it introduces a new treatment mechanism. While TNF inhibitors remain the first-line biologic treatment, the growing adoption of IL-23 inhibitors like AbbVie’s Skyrizi signals a potential shift in the treatment landscape. The availability of multiple IL-23 inhibitors offers patients and physicians more choices, potentially leading to improved outcomes by tailoring treatments to individual needs. This competition also encourages pharmaceutical companies to innovate and refine their offerings.

Spherix Global Insights’ Q4 2024 research reveals that roughly half of gastroenterologists view Tremfya as a substantial improvement over existing options, compared to only one-third for Omvoh. Over half of those surveyed prefer Tremfya as their IL-23 inhibitor of choice for Crohn’s disease, with only 20% selecting Omvoh. While Omvoh aims to address bowel urgency—a critical concern for Crohn’s disease patients—its success hinges on establishing a distinct value proposition against competitors.

The future of Omvoh in the Crohn’s disease market depends on Lilly’s ability to differentiate its efficacy and patient benefits compared to Tremfya and Skyrizi. The competition among these IL-23 inhibitors will likely drive further research and development, ultimately benefiting patients through more effective and targeted treatments. Market dynamics will be shaped by how effectively Lilly positions Omvoh, particularly in highlighting advantages beyond addressing bowel urgency.

Source link: https://www.globenewswire.com/news-release/2025/01/31/3018975/0/en/FDA-Approval-of-Eli-Lilly-s-Omvoh-for-Crohn-s-Disease-Adds-a-New-Option-but-Uptake-May-be-Hampered-by-US-Gastroenterologists-Brand-Preferences-Among-the-IL-23-Class-According-to-Sp.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.